Amarin Corporation PLC announced today (2/9) that its corporate partner, Edding, has progressed VASCEPA® (icosapent ethyl) for Hong Kong and Mainland China’s regulatory review processes. Based on the clinical data for VASCEPA®, including Phase III studies conducted by Amarin and Edding, Edding is seeking labeling with hopes of a decision by the Chinese National Products Administration (NMPA) by the end of 2021. Edding’s chief medical officer, James He, stated, “We are very glad to know that the applications for drug approval of VASCEPA were formally accepted by the National Medical Products Administration (NMPA) in Mainland China and the Department of Health in Hong Kong.”

Read more here.

More on: